Gingivitis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Gingivitis is an inflammatory condition affecting the gingival tissue, primarily caused by bacterial infection. Unlike periodontitis, gingivitis does not involve attachment loss or migration of the junctional epithelium. It is confined to the soft-tissue region of the gingival epithelium and connective tissue. Among all periodontal diseases, gingivitis is the most prevalent. It manifests in various forms based on clinical appearance, duration of infection, severity, and underlying causes. However, chronic gingivitis caused by plaque is the most observed variant. Clinical features of gingivitis include swelling, redness, tenderness, a shiny surface, and bleeding upon gentle probing. Although spontaneous bleeding is rare, gingivitis is typically painless, leading many patients to overlook the condition and delay seeking treatment. Gingivitis is primarily caused by microbial plaque deposits located within or near the gingival sulcus. The main microorganisms associated with the etiology of gingivitis include Streptococcus, Fusobacterium, Actinomyces, Veillonella, and Treponema species. Bacteroides, Capnocytophaga, and Eikenella may also contribute to the development of the disease. Based on its etiology, gingivitis can be classified into different types, including plaque-induced gingivitis, nutritional gingivitis, hormonal gingivitis, and drug-induced gingivitis. The key distinction between gingivitis and periodontitis is the noticeable attachment loss observed during periodontal probing in the latter condition. From a pathophysiological perspective, gingivitis can be divided into initial, early, and established stages, with periodontitis representing the advanced stage. If gingivitis progresses to periodontitis, it can result in connective tissue attachment loss, bone destruction, and, ultimately, tooth loss.
Thelansis’s “Gingivitis Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022
To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Gingivitis treatment modalities options for
eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Gingivitis across 8 MM market from the centre of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Gingivitis Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment